|
|
|
|
|
by colordrops
3341 days ago
|
|
This antiviral is extremely promising, and it boggles the mind how this has not gotten real funding. My cynical side thinks it would cut very deep into a lot of profits for all the various viral medications for lifetime diseases such as the HIV cocktail, herpes meds, and other viral illnesses, so there isn't much upside for a large company to fund this. |
|
[1] https://www.statnews.com/2016/04/28/gilead-hepatitis-c-reven...